Net loss: ($60.7M) (+30.8%); loss/share: ($0.68) (+40.4%); Quick Assets: $535.6M (+8.2%).
2019 Guidance: ARIKAYCE revenue: $133M – 138M.
INSM is advancing its planned regulatory filings in Japan in H1 2020.
The company appoints Martina Flammer, M.D., M.B.A., as Chief Medical Officer.
Topline results from the WILLOW study are expected in Q1 2020.
Previously: Insmed EPS misses by $0.01, beats on revenue (Oct. 30)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.